Search
Cell replacement therapy seeks to restore function in the body by replacing cells that are lost due to disease or injury with new, healthy cells. One disease for which this type of therapy holds particular promise is the degenerative neurological disorder Parkinson’s disease, which is characterized by symptoms related to movement.
Studies conducted in mice reveal a potential way to breach the defenses of pancreatic cancer tumors.
Learn how highly focused, intense radiation can stop lung cancer from growing after it has spread to a small number of sites.
Obtenga información sobre cómo la radiación intensamente focalizada y de alta dosis puede detener el crecimiento del cáncer pulmonar después de que se ha diseminado a una pequeña cantidad de sitios.
Meet David, a patient representative at MSK, who makes his voice heard is as a member of MSK’s LGBTQ Clinical Advisory Committee. Founded in 2017, the committee advises MSK staff on the clinical care of LGBTQ patients and provides strategic direction for the advancement of care for LGBTQ populations.
Patients like Michelle benefit from the specialized skills of experts in MSK’s Rare Breast Cancer Program.
Research fellow Shaniqua Hayes joined the Jason Lewis Lab at the Sloan Kettering Institute (SKI) and Memorial Hospital about a year ago, after attending an online postdoc recruiting event and picking up “good vibes” about SKI.
In a pivotal move to revolutionize the clinical research landscape, the MSK Clinical Research Innovation Consortium (CRIC) held its inaugural kick-off meeting in November 2025. Spearheaded by founding member MSK, the meeting welcomed new CRIC members Moffitt Cancer Center, Huntsman Cancer Institute, and the Tisch Cancer Center of Mount Sinai Health System.
In contrast with the findings of two international trials, Memorial Sloan Kettering Cancer Center data suggest the standard treatment – primary debulking surgery – may provide better outcomes in select patients when compared to neoadjuvant chemotherapy.
Memorial Sloan Kettering Cancer Center (MSK) today announced a $50 million gift from Jane and Daniel Och to advance MSK’s cutting-edge patient-care and research.